Skip to main navigation Skip to search Skip to main content

Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK

  • Vanessa Devine
  • , Rebecca A Gladstone
  • , Jessica Jones
  • , David Cleary
  • , Johanna M C Jefferies
  • , Stephen D Bentley
  • , Saul N Faust
  • , Stuart C Clarke

Research output: Contribution to journalArticlepeer-review

295 Downloads (Pure)

Abstract

This is the first description of the population structure of this collection of pneumococcal carriage isolates in the UK. This study sought to define dominant lineages and their dynamics over the study period. When a non-vaccine type (NVT) was detected in a vaccine type (VT) lineage in the pre-pneumococcal conjugate vaccine (PCV) era, that NVT was observed to expand, replacing the vaccine serotype. If it can be predicted which NVT/genotype combinations are likely to be involved in replacement, the clinical impact can be assessed, via the lineages antibiotic resistance and virulence determinants profile and the invasive potential of the serotype expressed. Establishing the population structure and serotype mixture of lineages in countries thinking about PCV implementation could therefore offer additional, geographically specific, information during the PCV selection process.
Original languageEnglish
Article numberVolume 3, Issue 6
Pages (from-to)1-9
Number of pages9
JournalMicrobial Genomics
Volume3
Issue number6
DOIs
Publication statusPublished (in print/issue) - 9 Jun 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Streptococcus pneumoniae
  • pneumococcal
  • vaccines
  • PCV
  • serotype
  • replacement
  • whole genome sequencing

Fingerprint

Dive into the research topics of 'Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK'. Together they form a unique fingerprint.

Cite this